I. Vlachogiannakos

发表

Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study

E. Rigopoulou, E. Hadziyannis, G. Papatheodoridis, 2018 .

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

E. Cholongitas, G. Touloumi, J. Petersen, 2016, Hepatology.

Bravo 48-hour Wireless pH Monitoring in Patients With Non-cardiac Chest Pain. Objective Gastroesophageal Reflux Disease Parameters Predict the Responses to Proton Pump Inhibitors

S. Fessatou, S. Ladas, K. Triantafyllou, 2012, Journal of neurogastroenterology and motility.

Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy

A. Georgiou, E. Hadziyannis, G. Papatheodoridis, 2016, Annals of gastroenterology.

Significance of serum HBV RNA in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients who discontinue effective antiviral therapy

F. Zoulim, G. Magiorkinis, E. Rigopoulou, 2022, Journal of viral hepatitis.

High levels of all-cause mortality among people who inject drugs in Greece in 2018--2022

A. Hatzakis, I. Goulis, I. Elefsiniotis, 2022, medRxiv.

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

M. Buti, T. Berg, R. Idilman, 2018, Journal of hepatology.

Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic hepatitis B

F. Zoulim, E. Rigopoulou, B. Testoni, 2020, Journal of viral hepatitis.

Serum HBsAg kinetics and usefulness of interferon‐inducible protein 10 serum in HBeAg‐negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate

A. Georgiou, C. Triantos, E. Hadziyannis, 2015, Journal of viral hepatitis.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

M. Buti, T. Berg, R. Idilman, 2017, Hepatology.

Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study

M. Kontogianni, M. Yannakoulia, P. Tsibouris, 2019, British Journal of Nutrition.

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.

M. Buti, R. Idilman, C. Yurdaydın, 2016, Journal of hepatology.

Validation of cutoffs for skeletal muscle mass index based on computed tomography analysis against dual energy X-ray absorptiometry in patients with cirrhosis: the KIRRHOS study

M. Kontogianni, M. Yannakoulia, M. Deutsch, 2019, Annals of gastroenterology.

The Presence of Myosteatosis Is Associated with Age, Severity of Liver Disease and Poor Outcome and May Represent a Prodromal Phase of Sarcopenia in Patients with Liver Cirrhosis

M. Kontogianni, E. Geladari, R. Tenta, 2023, Journal of clinical medicine.

P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC)

M. Buti, R. Idilman, C. Yurdaydın, 2015 .

HERACLIS‐HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg‐positive patients

E. Cholongitas, K. Mimidis, D. Christodoulou, 2023, Liver international : official journal of the International Association for the Study of the Liver.

High levels of all-cause mortality among people who inject drugs from 2018 to 2022.

D. Paraskevis, I. Goulis, V. Sypsa, 2024, The International journal on drug policy.